N

    NRX Pharmaceuticals Inc (NRXP)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $3.48
    -0.07 (-1.97%)

    Market Cap: $153.70M

    Last updated: Sep 01, 2026 at 10:00 AM ET

    Earnings

    Performance (10Y)

    Beat Rate
    47%(8/17)
    Avg Surprise
    -145.02%

    Upcoming Estimates

    Sep 30, 2026
    EPS Consensus$-0.08
    Range$-0.08 - $-0.08
    1 analysts
    EPS RevisionsNo revisions (7d)
    0
    1
    30d
    EPS Estimate Drift
    90d ago$0.04+150.0%
    60d ago$0.04+150.0%
    30d ago$0.04+150.0%
    7d ago$0.04+150.0%
    Current$-0.08
    Revenue Consensus
    $1M
    Range$1M - $2M
    2 analysts
    Dec 31, 2026
    EPS Consensus$-0.04
    Range$-0.04 - $-0.04
    1 analysts
    Revenue Consensus
    $-21854840
    Range$-23685340 - $-20024340
    2 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$-0.04---
    Sep 26EST
    		-$-0.08---
    Jun 26
    		$-0.18$-0.09-100.00%Miss+81.6%
    Mar 26
    		$-0.04N/A+63.64%Beat+88.2%
    Dec 25
    		$0.18$-0.08+329.13%Beat+123.8%
    Sep 25
    		$-0.51$-0.02-2450.00%Miss-240.0%
    Jun 25
    		$-0.98$-0.23-326.09%Miss-30.7%
    Mar 25
    		$-0.34$-0.53+35.85%Beat+54.1%
    Dec 24
    		$-0.77$-0.37-108.11%Miss-54.0%
    Sep 24
    		$-0.15N/A+77.27%Beat+78.6%
    Jun 24
    		$-0.75$-0.69-8.70%Miss+37.5%
    Mar 24
    		$-0.74$-0.55-34.55%Miss-362.5%
    Dec 23
    		$-0.50$-0.80+37.50%Beat+68.8%
    Sep 23
    		$-0.70$-1.15+39.13%Beat+50.0%
    Jun 23
    		$-1.20$-1.40+14.29%Beat-9.1%
    Mar 23
    		$-0.16$-0.14-14.29%Miss+23.8%
    Dec 22
    		$-1.60$-1.45-10.34%Miss-201.9%
    Sep 22
    		$-1.40$-1.40+0.00%Beat-250.0%
    Jun 22
    		$-1.10$-1.00-10.00%Miss+83.1%
    Mar 22
    		$-0.21N/AN/ABeat-31.2%
    Dec 21
    		$-0.53N/AN/ABeat+76.5%
    Sep 21
    		$-0.40N/AN/ABeat-700.0%
    Jun 21
    		$-6.51$0.00N/AMiss-10750.0%
    Mar 21
    		$-0.16N/AN/ABeat-260.0%
    Dec 20
    		$-2.26N/AN/ABeat-22488.0%
    Sep 20
    		$-0.05N/AN/ABeat-600.0%
    Jun 20
    		$-0.06N/AN/ABeat-300.0%
    Mar 20
    		$0.10N/AN/ABeat+400.0%
    Dec 19
    		$-0.01N/AN/ABeat-131.1%
    Sep 19
    		$0.01N/AN/ABeat-67.8%
    Jun 19
    		$0.03N/AN/ABeat+511.0%
    Mar 19
    		$0.02N/AN/ABeat+16.3%
    Dec 18
    		$0.03N/AN/ABeat+125.9%
    Sep 18
    		$0.03N/AN/ABeat-
    Jun 18
    		$-0.01N/AN/ABeat-
    Mar 18
    		$0.02N/AN/ABeat-
    Dec 17
    		$-0.12N/AN/ABeat-

    Key Metrics

    Valuation
    P/E Ratio-6.37EV/EBITDA-0.15x
    Price/FCFN/AFCF YieldN/A
    Profitability
    Profit Margin0.00%Operating Margin-590.00%
    ROE-683.00%ROIC-2846.04%
    Financial Health
    Debt/Equity-4.65xInterest CoverageN/A
    Current Ratio0.86xQuick Ratio0.86x
    Trading Statistics
    Beta2.18Avg Volume1.15M
    52-Week High$5.0552-Week Low$1.62

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$3.51
    SMA 20$3.40
    SMA 50$3.70
    SMA 200$2.83
    EMA 10$3.50
    EMA 20$3.50
    EMA 50$3.56
    EMA 200$3.12

    MACD

    Line: -0.03Signal: -0.06Hist: 0.04

    ADX

    ADX: 20.0+DI: 23.6-DI: 15.8

    Aroon & PSAR

    Aroon Up36.0
    Aroon Down12.0
    PSAR$3.19

    Bollinger Bands

    Upper Band$3.75
    Lower Band$3.05
    %B Position2084%(Upper)
    Band Width0.61

    RSI (14-Day)

    Neutral
    48.6

    Momentum Oscillators

    Stoch %K76.7
    Stoch %D67.8
    Williams %R-35.0
    ROC (10d)1.5%
    Momentum0.05
    CCI (20d)36.5
    MFI (14d)56.8

    Volatility Measures

    ATR (14d)$0.28(7.9%)
    StdDev (20d)0.18
    Hist Vol82.2%(High)

    Volume Flow

    VWAP$3.48
    OBV36.9M
    AD Line11.4M
    CMF (20d)-0.246

    Volume Metrics

    Avg Vol (20d)1.2M
    Vol Ratio0.4x(Low)
    VWMA (20d)$3.43

    Pivot Points

    R3$3.83
    R2$3.76
    R1$3.65
    Pivot Point$3.58
    S1$3.47
    S2$3.40
    S3$3.29

    Advanced Oscillators

    TSI-3.16
    Ultimate Osc49.8
    KST-47.85

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$1.10M$1.07M$983,000$242,000$0$4,000$4,000$0$0$8,000$8,000$0
    Cost of Revenue$843,000$796,000$508,000$138,000N/A$2,000$1,000$2,000$1,000$1,000$1,000$2,000
    Gross Profit$258,000$272,000$475,000$104,000N/A$2,000$-1,000$-2,000$-1,000$-1,000$-1,000$-2,000
    Operating Expenses$6.76M$5.02M$5.07M$4.22M$3.73M$3.85M$3.63M$3.02M$7.05M$6.00M$4.41M$5.81M
    R&D$2.12M$1.31M$558,000$1.43M$987,000$804,000$1.04M$611,000$2.80M$1.75M$2.53M$3.31M
    SG&A$4.75M$3.81M$4.57M$2.81M$2.74M$2.94M$2.60M$2.41M$4.25M$4.25M$1.87M$2.49M
    Operating Income$-6,505,000$-4,748,000$-4,594,000$-4,118,000$-3,730,000$-3,847,000$-3,634,000$-3,022,000$-7,050,000$-5,998,000$-4,406,000$-5,808,000
    Interest Income$0$5,000$4,000$2,000$2,000$4,000$4,000$6,000$7,000$27,000$74,000$119,000
    Interest Expense$240,000$233,000$671,000$0$0$0$0$0$849,000$230,000$80,000$40,000
    Income Before Tax$-16,520,000$-1,430,000$360,000$-5,890,000$-17,581,000$-5,512,000$-9,078,000$-1,623,000$-7,897,000$-6,528,000$-4,332,000$-6,062,000
    Income Tax Expense$0$0$0$0$0$0$0$0$0$-42,276$-1,394,000$40,000
    Net Income$-16,520,000$-1,430,000$360,000$-5,890,000$-17,581,000$-5,512,000$-9,078,000$-1,623,000$-7,897,000$-6,528,000$-4,332,000$-6,062,000
    EBITDA$-16,214,000$-1,032,000$1.13M$-5,849,000$-17,581,000$-5,511,000$-9,077,000$-1,621,000$-7,047,000$-6,297,000$-4,251,000$-6,020,000
    EBIT$-16,280,000$-1,197,000$1.03M$-5,890,000$-3,730,000$-5,512,000$-9,078,000$-1,623,000$-7,048,000$-6,298,000$-4,252,000$-6,022,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about NRXP

    News

    NRx Advances Ketamine Bid After FDA Review Clears Drug

    NRx Pharmaceuticals is moving closer to launching preservative-free ketamine in 2026 after a favorable FDA review. The company is also pursuing approval for NRX-100 for depression and NRX-101 for suicidal bipolar depression and treatment-resistant depression, with new clinical locations and research initiatives underway. NRx's financial position shows a narrowed net loss and increased cash due to a public stock offering.

    MyChesCo•8/26/26•
    Bullish

    FDA First Cycle Review of Preservative-Free Ketamine ANDA with No Drug Related Major Deficiencies Noted for Suicidal Bipolar Depression Treatment from NRx Pharmaceuticals, Inc. (Nasdaq: NRXP)

    NRx Pharmaceuticals, Inc. (NRXP) announced that the FDA completed a first-cycle review of its Abbreviated New Drug Application (ANDA) for preservative-free ketamine, noting no drug-related major deficiencies. The company also reported strong financial results for Q2 2026, with sufficient cash to fund operations for at least one year and progress in commercializing ketamine for suicidal bipolar depression. Additionally, NRXP's subsidiary, NRx Defense Systems, Inc., was selected by DARPA for contract negotiations for a clinical trial on a robotic TMS and NRX-101 combination for depression.

    FinancialContent•8/20/26•
    Bullish

    BTIG Research Reaffirms "Buy" Rating for NRx Pharmaceuticals (NASDAQ:NRXP)

    BTIG Research has reaffirmed a "Buy" rating for NRx Pharmaceuticals (NASDAQ:NRXP) and set a $10 price target, suggesting a potential upside of 191.55% from its current price of $3.43. This comes despite NRx Pharmaceuticals reporting a quarterly loss of $0.44 per share and revenue of $1.10 million, both missing analyst expectations. Analyst sentiment for NRXP is generally positive, with a "Moderate Buy" consensus rating and an average price target of $34.50 among six analysts.

    MarketBeat•8/18/26•
    Neutral

    NRX Pharmaceuticals Reports Q2 2026 Results: Full Earnings Call Transcript

    NRX Pharmaceuticals announced a reduced net loss of $18.0 million in the first half of 2026 and improved cash reserves to $26.7 million, driven by a recent public offering. The company is advancing key strategic initiatives, including FDA reviews for ketamine products, a military-funded trial for NRX101 with robotic TMS for treatment-resistant depression, and the acquisition of GeNeuro assets to develop treatments for ALS and other neurological disorders, expecting non-dilutive funding for the latter. Management expressed optimism for expanded market opportunities for NRX101 and the potential for international implications of their drug developments.

    Sahm•8/18/26•
    Bullish

    Press Release: NRx Pharmaceuticals (Nasdaq:NRXP) Reports Second Quarter 2026 Financial Results and Provides Corporate Update; Conference Call to Be Held on Monday, August 17th at 4:30pm ET

    NRx Pharmaceuticals (Nasdaq:NRXP) has reported its financial results for the second quarter of 2026. The company also provided a corporate update, with a conference call scheduled for Monday, August 17th, at 4:30 PM ET to discuss these results and updates.

    Moomoo•8/17/26•
    Neutral

    Frequently Asked Questions About NRXP

    Does NRXP pay dividends?
    NRX Pharmaceuticals Inc (NRXP) does not currently pay a regular dividend.
    What is NRXP's market cap?
    NRX Pharmaceuticals Inc (NRXP) has a market capitalization of $153.70M with a current stock price of $3.48.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In